Nextera joins the BIO International Convention

May 18, 2020 | Meet us

CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO International Convention June 8^th – 12^th. Book us for a digital meeting and we will present our unique NextCore Immunology platform. Learn how this technology can leverage the target and drug discovery in complex immunological diseases. https://www.bio.org/events/bio-digital

← Previous Next →

Recent

Nextera’s NextCore technology applied to develop a unique peptide activator of the tissue injury Factor-VII activating protease (FSAP) in human plasma
Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies
Nextera AS announces strategic collaboration with Zelluna Immunotherapy AS on development of optimized TCRs for redirected cancer immunotherapy
NextCore-generated state-of-the-art TCR-Like antibodies in celiac disease published in Science Immunology.
Nextera appoints Dr. Bent Jakobsen to the Board of Directors

Nextera joins the BIO International Convention

Recent

Sort by

Nextera AS

Contact

Navigation

Recent news

Nextera’s NextCore technology applied to develop a unique peptide activator of the tissue injury Factor-VII activating protease (FSAP) in human plasma

Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies